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Thyroid replacement therapy, thyroid stimulating hormone  
concentrations, and long term health outcomes in patients with 
hypothyroidism: longitudinal study
Rasiah Thayakaran,1* Nicola J Adderley,1* Christopher Sainsbury,1,2 Barbara Torlinska,1  
Kristien Boelaert,3,4,5 Dana Šumilo,1 Malcolm Price,1 G Neil Thomas,1 Konstantinos A Toulis,1,6 
Krishnarajah Nirantharakumar1,5,7
AbstrAct
Objective
To explore whether thyroid stimulating hormone 
(TSH) concentration in patients with a diagnosis of 
hypothyroidism is associated with increased all cause 
mortality and a higher risk of cardiovascular disease 
and fractures.
Design
Retrospective cohort study.
setting
The Health Improvement Network (THIN), a database 
of electronic patient records from UK primary care.
ParticiPants
Adult patients with incident hypothyroidism from 1 
January 1995 to 31 December 2017.
exPOsure
TSH concentration in patients with hypothyroidism.
Main OutcOMe Measures
Ischaemic heart disease, heart failure, stroke/
transient ischaemic attack, atrial fibrillation, 
any fractures, fragility fractures, and mortality. 
Longitudinal TSH measurements from diagnosis 
to outcomes, study end, or loss to follow-up were 
collected. An extended Cox proportional hazards 
model with TSH considered as a time varying covariate 
was fitted for each outcome.
results
162 369 patients with hypothyroidism and 863 072 
TSH measurements were included in the analysis. 
Compared with the reference TSH category (2-2.5 
mIU/L), risk of ischaemic heart disease and heart 
failure increased at high TSH concentrations (>10 
mIU/L) (hazard ratio 1.18 (95% confidence interval 
1.02 to 1.38; P=0.03) and 1.42 (1.21 to 1.67; 
P<0.001), respectively). A protective effect for heart 
failure was seen at low TSH concentrations (hazard 
ratio 0.79 (0.64 to 0.99; P=0.04) for TSH <0.1 mIU/L 
and 0.76 (0.62 to 0.92; P=0.006) for 0.1-0.4 mIU/L). 
Increased mortality was observed in both the lowest 
and highest TSH categories (hazard ratio 1.18 (1.08 
to 1.28; P<0.001), 1.29 (1.22 to 1.36; P<0.001), and 
2.21 (2.07 to 2.36; P<0.001) for TSH <0.1 mIU/L, 
4-10 mIU/L, and >10 mIU/L. An increase in the risk 
of fragility fractures was observed in patients in the 
highest TSH category (>10 mIU/L) (hazard ratio 1.15 
(1.01 to 1.31; P=0.03)).
cOnclusiOns
In patients with a diagnosis of hypothyroidism, no 
evidence was found to suggest a clinically meaningful 
difference in the pattern of long term health outcomes 
(all cause mortality, atrial fibrillation, ischaemic heart 
disease, heart failure, stroke/transient ischaemic 
attack, fractures) when TSH concentrations were 
within recommended normal limits. Evidence was 
found for adverse health outcomes when TSH 
concentration is outside this range, particularly above 
the upper reference value.
Introduction
Hypothyroidism is a highly prevalent global health 
problem that can substantially affect patients’ wellbeing.1 
Lifelong treatment with thyroid hormone (replacement 
therapy) is needed when the diagnosis of persistent 
thyroid hormone deficiency is confirmed; consequently, 
levothyroxine is one of the most commonly prescribed 
drugs in Western countries,2 3 and this is likely to increase 
further in the foreseeable future.4
Long term adverse health outcomes in patients with 
thyroid dysfunction and treatment targets to optimise 
these outcomes, generally monitored by serial 
measurements of thyroid stimulating hormone (TSH), 
have been extensively investigated. In particular, 
the cardiovascular effect of thyroid dysfunction and 
the negative ramifications of clinical (overt) thyroid 
hypofunction, mediated by changes in systemic vascular 
resistance, hypertension, hypercholesterolaemia, and 
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WhAt Is AlreAdy knoWn on thIs topIc
Hypothyroidism is highly prevalent and can substantially affect patients’ 
wellbeing
No specific optimal target for thyroid stimulating hormone (TSH) concentration 
exists in the context of thyroid hormone replacement
Whether variation in TSH concentration within normal limits may significantly 
affect patients’ outcomes remains unclear
WhAt thIs study Adds
No clinically meaningful difference in the pattern of long term health outcomes 
(mortality, cardiovascular disease, fractures) was seen when TSH concentrations 
were within recommended normal limits
Compared with the reference TSH category (2-2.5 mIU/L), risk of ischaemic 
heart disease, heart failure, and fragility fractures was increased at high TSH 
concentrations (>10 mIU/L)
Mortality was increased in both the lowest and highest TSH categories (<0.1 and 
>4 mIU/L), compared with 2-2.5 mIU/L
This study provides strong support for the current recommendations on the 
clinical management of hypothyroid patients and validates with hard evidence 
the latest guidelines
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accelerated atherosclerosis, are well documented.5 6 
One of the targets for treatment with thyroid hormone 
replacement is to reverse such adverse effects. Current 
guidelines in Europe and the US recommend that 
replacement therapy should be aimed at resolving 
symptoms and achieving “normalisation” of TSH.7  8 
However, no specific optimal target for TSH exists in 
the context of thyroid hormone replacement. This 
uncertainty is reflected in the guidelines proposed 
by the American Thyroid Association Task Force 
and the statement issued by the British Thyroid 
Association Executive Committee, which suggest a 
wide range for TSH, 0.4-4.0 mIU/L, as an indication 
for optimal replacement,7 8 after emphasising the 
scarcity of relevant evidence. TSH concentrations in 
this wide target range may be achieved by different 
doses of levothyroxine. However, from a physiological 
standpoint, a continuum of effects may plausibly occur 
across the spectrum of normal TSH concentrations9; 
the same human heart might behave differently at 
a pace dictated by a TSH concentration of 0.4 mIU/L 
compared with one of 4 mIU/L, both of which are 
considered normal. Evidence indicates that TSH 
and circulating thyroid hormone concentrations are 
quite tightly regulated on an individual basis,10 but 
determining an individual’s set point is not part of 
routine clinical practice, and replacement treatment is 
generally targeted in a wide reference range.
Although age specific TSH targets may be considered, 
especially in the context of high cardiovascular 
risk,7 this strategy is based on the findings of studies 
in euthyroid or subclinically hypothyroid people. 
However, patients with hypothyroidism need a higher 
concentration of serum free thyroxine to achieve a 
normal TSH concentration compared with euthy-
roid controls.11 Consequently, a hypothyroid patient 
receiving thyroid replacement therapy and a euthyroid 
patient with comparable TSH concentrations are not 
expected to have comparable circulating free thyroxine 
concentrations. The same is true of free triiodothyronine 
concentrations in patients who have had total 
thyroidectomy.12 Therefore, any extrapolations on the 
association between optimal TSH concentrations and 
cardiovascular outcomes in patients receiving thyroid 
replacement therapy based on studies in euthyroid 
patients should be treated with caution, as serum free 
thyroxine and free triiodothyronine concentrations 
(relevant to cardiovascular physiology) may differ 
significantly between the two groups.
Moreover, in primary studies in euthyroid or 
subclinically hypothyroid patients,13 and in the related 
meta-analyses and reviews,14-20 thyroid function testing 
was done only at baseline. The potential therefore 
exists for misclassification bias in all estimates to date 
as a result of established and anticipated changes in 
thyroid hormone production over the life course of 
a patient, as well as instances of transient thyroid 
dysfunction (such as non-thyroidal illness or following 
the hyperthyroid phase of a painless thyroiditis). A 
person classified as euthyroid at baseline might go 
on to develop hypothyroidism, overt or subclinical, 
whereas those classified as subclinically hypothyroid 
might be found to be euthyroid on follow-up thyroid 
function testing.
Similar limitations affect studies assessing the 
association between thyroid dysfunction and 
risk of fracture,21 22 and whether variation in TSH 
concentration within normal limits may significantly 
affect the skeleton or whether any effect is insignificant 
in clinical terms (fracture risk remains unaffected) 
remains unclear. This is further challenged by evidence 
suggesting that free thyroxine concentrations are the 
main driver of the above clinical outcomes.23 24
The aim of this study was to explore whether TSH 
concentration is associated with an increased risk 
of cardiovascular diseases, mortality, and fractures 
in patients with a diagnosis of hypothyroidism. We 
treated TSH as a time varying covariate to account 
for variation in TSH concentration over time within 
individuals.
Methods
Data source
We extracted data from The Health Improvement 
Network (THIN) database, an unobtrusive medical 
data collection scheme that collects anonymised 
information on patients from UK general practices that 
use Vision electronic medical records software. THIN 
contains data for approximately 15 million patients 
registered with 787 practices. The database consists 
of coded information on patients’ characteristics, 
drug prescriptions, diagnoses, consultations, and 
diagnostic test results.25
study design
This was a retrospective cohort study. The study period 
was 1 January 1995 to 31 December 2017.
study population
To ensure high data quality, general practices were 
eligible for inclusion in the study from 12 months 
after the latest of the practice acceptable mortality 
reporting date (a measure of data quality)26 and the 
date on which the practice began using electronic 
medical records. We included adults aged 18 years or 
above with a diagnosis of hypothyroidism; diagnosis 
was ascertained by a record of a clinical (Read) code. 
For each of the outcomes, we excluded patients with 
a record of that outcome at baseline. We also excluded 
patients without at least one measurement of TSH 
concentration after the diagnosis of hypothyroidism.
Patients were eligible for inclusion one year after 
joining the practice. To mitigate immortal time bias, 
we included only patients with an incident (new) 
record of hypothyroidism after the patient became 
eligible to join the study. The index date was the date 
of an incident record of a diagnosis of hypothyroidism. 
For each outcome, we followed patients from the 
index date until the earliest of the following events 
(exit date): patient died, last data collection from the 
practice, patient left the practice, patient diagnosed as 
having outcome, or study end date.
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exposure, outcomes, and covariates
The exposure was TSH concentration in patients 
with hypothyroidism. The primary outcomes were 
incidences of cardiovascular diseases, including 
ischaemic heart disease, heart failure, and stroke/
transient ischaemic attack. Secondary outcomes were 
incidences of mortality, atrial fibrillation, all fractures, 
and fragility fractures. We considered fractures of the 
spine, hip, distal radius, and humerus to be fragility 
fractures. We used relevant clinical (Read) codes to 
define outcomes; these codes have been validated in 
several studies. In the UK, GPs are required to maintain 
a mandatory register of patients with ischaemic heart 
disease, heart failure, stroke/transient ischaemic 
attack, and atrial fibrillation as part of the Quality and 
Outcomes Framework; these diagnoses are therefore 
well recorded in primary care. Mortality data and 
clinical codes for cardiovascular diseases in THIN have 
been previously validated.27-29
Covariates included in the models were sex, age, 
socioeconomic status (measured using fifths of 
Townsend deprivation),30 smoking status (smoker/
non-smoker), body mass index, prescription for 
lipid lowering drug, diabetes, hypertension, and 
prescription for thyroxine as recorded at baseline. We 
categorised body mass index (kg/m2) as less than 25 
(normal weight), 25-30 (overweight), and above 30 
(obese).
We treated TSH as a time varying covariate measured 
annually. For patients with multiple TSH values 
recorded within a single year, we used the mean value. 
We treated TSH concentration as a categorical variable 
to explore clinically meaningful thresholds: below 0.1, 
0.1-0.4, 0.4-1, 1-1.5, increasing increments of 0.5 up 
to 4, and then 4-10 and >10 mIU/L. We defined TSH 
categories after reviewing the literature and consulting 
clinical experts. To explore variation within the usual 
normal limits, we selected increments of 0.5 mIU/L so 
that resulting TSH categories did not cross the reported 
individual reference range for TSH.31 We selected TSH 
concentrations above 10 mIU/L and below 0.1 mIU/L 
as the thresholds for unequivocal diagnosis of overt 
hypothyroidism and hyperthyroidism respectively. 
We assumed the remaining categories (TSH 0.1-
0.4 and 4-10 mIU/L) to include subclinical thyroid 
dysfunction, serving both ease of interpretation and 
biological plausibility.
Missing data
We replaced missing values for the annual (time 
varying) TSH concentration by carrying forward the 
last recorded observation.32-34 To assess the accuracy 
of this approach in reproducing missing data, we 
validated imputed/carried forward values against 
observed values by using the following method: for 
each year, we calculated the mean of all observed TSH 
values and the mean of all imputed TSH values; we 
then plotted observed mean yearly TSH and imputed 
mean yearly TSH (with upper and lower confidence 
limits) against follow-up year to check that observed 
mean values fell within the confidence interval for 
imputed mean values, thereby ensuring that the 
imputed data were representative of the original study 
dataset. In addition, we did a sensitivity analysis for 
the mortality outcome by using multiple imputation 
to impute missing TSH values; covariates used in 
the imputation were sex, age, body mass index, fifth 
of Townsend deprivation, smoking status, diabetes, 
hypertension, and levothyroxine prescription 
(supplementary methods 1). We treated missing values 
for other covariates (body mass index, smoking status, 
and fifth of Townsend deprivation) as a separate 
missing category for each variable.35
analysis
We used extended Cox proportional hazards models 
to estimate hazard ratios and their corresponding 
95% confidence intervals for each outcome 
(supplementary methods 2).36 For each of the seven 
outcomes (ischaemic heart disease, heart failure, 
stroke/transient ischaemic attack, atrial fibrillation, 
all fractures, fragility fractures, and mortality), the 
Cox proportional hazards model was adjusted for the 
following baseline covariates: age, sex, body mass 
index, smoking status, fifth of Townsend deprivation, 
prescription for lipid lowering drug, diabetes, 
hypertension, and prescription for levothyroxine. For 
mortality, the model was also adjusted for Charlson 
comorbidity index. We considered TSH as a categorical 
time varying covariate. We calculated hazard ratios 
for each TSH category compared with the reference 
category (2-2.5 mIU/L) to investigate the incremental 
change in risk of cardiovascular diseases or fractures. 
We did subgroup analyses by age group (≤65 years and 
>65 years) and sex. We used R 3.4.1 for all analyses.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for dsign or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
Dissemination of the findings to participants is not 
possible owing to the use of an anonymised dataset.
results
The study population included 162 369 patients 
with hypothyroidism; we excluded 1930 patients 
with a baseline TSH measurement only and no 
subsequent measurement. The remaining 160 439 
included patients contributed a total of 1 073 038 
person years, with a median follow-up of 6 years 
(supplementary table A); 23.2% (n=37 226) of 
patients were men, and 76.8% (n=123 213) were 
women. The mean age of patients at the time of 
diagnosis of hypothyroidism was 58.43 (SD 17.15) 
years. A total of 863 072 TSH measurements were 
collected for the analysis.
Table 1 shows baseline characteristics of patients 
with hypothyroidism for each of the seven outcomes 
(ischaemic heart disease, heart failure, stroke/
transient ischaemic attack, atrial fibrillation, all 
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fractures, fragility fractures, and mortality). The 
number of patients included in the analysis for each of 
the outcomes varies slightly, as patients with a record 
of the outcome at baseline were excluded.
cardiovascular diseases
Table 2 shows the number of patients who developed 
each of the outcomes. Incidence rates were higher in 
men than in women.
After adjusting for potential confounders, we 
found a statistically significant increase in risk of 
ischaemic heart disease and heart failure at high 
TSH concentrations (>10 mIU/L) compared with the 
reference category (2-2.5 mIU/L) (hazard ratio 1.18 
(95% confidence interval 1.02 to 1.38; P=0.03) and 
1.42 (1.21 to 1.67; P<0.001), respectively (fig 1 and 
supplementary tables B and C). This was not the case 
for stroke/transient ischaemic attack; however, the risk 
was marginally reduced at TSH concentrations of 3-3.5 
mIU/L (hazard ratio 0.86 (0.75 to 0.99; P=0.04) and 
4-10 mIU/L (0.90 (0.80 to 1.00; P=0.05)) (fig 1 and 
supplementary table D). At low TSH concentrations 
(<0.4 mIU/L), no association with ischaemic heart 
disease or stroke/transient ischaemic attack was 
present, but we observed a protective effect for heart 
failure (hazard ratio 0.79 (0.64 to 0.99; P=0.04) for 
TSH <0.1 mIU/L and 0.76 (0.62 to 0.92; P=0.006) for 
0.1-0.4 mIU/L).
In the adjusted model, we observed no association 
between risk of atrial fibrillation and the lowest or 
highest TSH categories. However, we found a marginal 
protective effect at TSH concentrations of 0.1-0.4 
mIU/L (hazard ratio 0.86 (0.74 to 1.00; P=0.05) (fig 1 
and supplementary table E).
We obtained similar results in age (≤65 and >65 
years) and sex stratified analyses (supplementary 
tables B-E). The association between the highest 
TSH concentration and increased risk of heart failure 
persisted in all subgroups, whereas the association 
with increased risk of ischaemic heart disease remained 
significant only in patients aged 65 years or under. 
The association between the lowest TSH categories 
and reduced risk of heart failure remained significant 
only in women and patients aged over 65 years. The 
protective effect on stroke/transient ischaemic attack 
of TSH concentrations of 3-10 mIU/L was evident 
only in women and patients aged over 65 years. TSH 
below 0.4 mIU/L was protective for atrial fibrillation 
table 1 | baseline characteristics of patients with hypothyroidism included in each of the seven analyses. values are numbers (percentages) unless 
stated otherwise
characteristic iHD (n=145 161)
Heart failure 
(n=155 210)
stroke/tia 
(n=152 624)
atrial fibrillation 
(n=151 651)
all fractures 
(n=129 778)
Fragility fractures 
(n=146 775)
Mortality 
(n=160 439)
Age (years):              
 Mean (SD) 56.8 (16.8) 57.7 (16.9) 57.5 (16.9) 57.3 (16.8) 57.8 (16.8) 57.8 (16.8) 58.4 (17.1)
 Median (iQR) 56.4 (44.5-69.2) 57.7 (45.4-70.6) 57.4 (45.2-70.4) 57.2 (45.1-69.9) 57.7 (45.5-70.6) 57.7 (45.5-70.6) 58.4 (45 9-71.6)
Male sex 30 273 (20.9) 34 861 (22.5) 34 354 (22.5) 33 222 (21.9) 28 862 (22.2) 34 429 (23.5) 37 226 (23.2)
Follow-up period (years):          
 Mean (SD) 6.6 (4.4) 6.7 (4.4) 6.6 (4.4) 6.6 (4.4) 6.5 (4.4) 6.6 (4.4) 6.7 (4.4)
 Median (iQR) 6 (-10) 6 (3-10) 6 (3-10) 6 (3-10) 6 (3-9) 6 (3-10) 6 (3-10)
Townsend fifth:        
 1 31 853 (21.9) 33 758 (21.8) 33 197 (21.8) 32 814 (21.6) 28 417 (21.9) 31 941 (21.8) 34 741 (21.7)
 2 28 315 (19.5) 30 207 (19.5) 29 710 (19.5) 29 444 (19.4) 25 197 19.4) 28 533 (19.4) 31 185 (19.4)
 3 27 481 (18.9) 29 414 (19.0) 28 956 (19.0) 28 715 (18.9) 24 589 (18.9) 27 839 (19.0) 30 446 (19.0)
 4 23 118 (15.9) 24 903 (16.0) 24 526 (16.1) 24 459 (16.1) 20 729 (16.0) 23 559 (16.1) 25 882 (16.1)
 5 15 723 (10.8) 17 067 (11.0) 16 660 (10.9) 16 769 (11.1) 13 996 (10.8) 16 022 (10.9) 17 740 (11.1)
 Missing 18 671 (12.9) 19 861 (12.8) 19 575 (12.8) 19 450 (12.8) 16 850 (13.0) 18 881 (12.9) 20 445 (12.7)
Body mass index:              
 <25 46 076 (31.7) 48 831 (31.) 47 736 (31.3) 47 484 (31.3) 40 848 (31.5) 45 697 (31.1) 50 309 (31.4)
 25-30 43 055 (29.7) 46 819 (30.2) 45 924 (30.1) 45 652 (30.1) 39 061 (30.1) 44 347 (30.2) 48 476 (30.2)
 >30 38 029 (26.2) 40 971 (26.4) 40 660 (26.6) 40 241 (26.5) 34 015 (26.2) 39 160 (26.7) 42 414 (26.4)
 Missing 18 001(12.4) 18 589 (12.0) 18 304 (12.0) 18 274 (12.1) 15 854 (12.2) 17 571 (12.0) 19 240 (12.0)
Smoking:              
 Non-smokers 116 590 (80.3) 125 160 (80.6) 123 215 (80.7) 121 872 (80.4) 104 872 (80.8) 118 486 (0.7) 129 774 (80.9)
 Smokers 22 934 (15.8) 24 217 (15.6) 23 621 (15.5) 24 038 (15.9) 19 738 (15.2) 22 684 (15.5) 24 638 (15.4)
 Missing 5637 (3.9) 5833 (3.8) 5788 (3.8) 5741 (3.8) 5168 (4.0) 5605 (3.8) 6027 (3.8)
Drugs:              
 Baseline levothy oxine 118 597 (81.7) 126 926 (81.8) 124 760 (81.7) 124 205 (81.9) 106 226 (81.9) 120 046 (81.8) 130 856 (81.6)
 Levothyroxine during follow-up 140 449 (96.8) 150 189 (96.8) 147 720 (96.8) 146 828 (96.8) 125 649 (96.8) 142 053 (96.8) 155 191 (96.7)
 Base ine lipid lowering drug 26 854 (18.5) 35 827 (23.1) 33 650 (22.0) 34 225 (22.6) 30 388 (23.4) 34 824 (23.7) 38 887 (24.2)
Medical conditions at baseline:        
 Hypertension 37 269 (25.7) 42 879 (27.6) 41 149 (27.0) 40 842 (26.9) 36 042 (27.8) 40 870 (2.8) 45 736 (28.5)
 Diabetes 11 846 (8.2) 13 959 (9.0) 13 772 (9.0) 13 633 (9.0) 12 030 (9.3) 13 822 (9.4) 15 255 (9.5)
Charlson comorbidity index:              
 0 97 753 (67.3) 101 230 (65.2) 101 234 (66.3) 98 739 (65.1) 83 952 (64.7) 93 934 (64. ) 101 234 (63.1)
 1 34 379 (23.7) 37 857 (24.4) 36 080 (23.6) 36 416 (24.0) 30 833 (23.8) 35 318 (24.1) 39 088 (24.4)
 2 7723 (5.3) 9503 (6.1) 8658 (5.7) 9424 (6.2) 8350 (6.4) 9725 (6.6) 11 092 (6.9)
 3 3449 (2.4) 4229 (2.7) 4158 (2.7) 4376 (2.9) 4025 3.1) 4675 (3.2) 5367 (3.3)
 ≥4 1857 (1.3) 2391 (1.5) 2494 (1.6) 2696 (1.8) 2618 (2.0) 3123 (2.1) 3658 (2.3)
iHD=ischaemic heart disease; iQR=interquartile range; TiA=transient ischaemic attack.
 o
n
 3 Septem
ber 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l4892 on 3 September 2019. Downloaded from 
RESEARCH
the bmj | BMJ 2019;366:l4892 | doi: 10.1136/bmj.l4892 5
in women, and TSH 0.1-0.4 mIU/L was protective for 
atrial fibrillation in patients aged 65 years or under.
all cause mortality
In the adjusted model, both the lowest and highest 
TSH concentrations were associated with increased 
mortality compared with the reference TSH category 
(hazard ratio 1.18 (1.08 to 1.28; P<0.001), 1.29 (1.22 
to 1.36; P<0.001), and 2.21 (2.07 to 2.36; P<0.001) for 
TSH <0.1 mIU/L, 4-10 mIU/L, and >10 mIU/L (fig 1 and 
supplementary table F).
In sex stratified subgroup analysis, the associations 
between the lowest and highest TSH concentrations 
and increased mortality remained significant in 
both men and women. We observed some evidence 
of reduced mortality in men with TSH 3-3.5 mIU/L 
(hazard ratio 0.88 (0.77 to 0.99). In age stratified 
analysis, the association between increased mortality 
and highest TSH remained in both the younger and 
older subgroups, but the association with lowest TSH 
became non-significant.
Fractures
In the adjusted model, we found no association between 
low or high TSH and risk of all fractures; however, we 
observed an increase in risk of fragility fractures at 
TSH concentrations above 10 mIU/L compared with 
the reference category (hazard ratio 1.15 (1.01 to 1.31; 
P=0.03)) (fig 1 and supplementary table G and H). 
This was predominantly driven by women and older 
patients (hazard ratio 1.18 (1.02 to 1.35) and 1.37 
(1.17 to 1.61), respectively); the association was non-
significant in men and patients aged 65 years or under. 
In age stratified analysis, we also found some evidence 
of a reduction in risk of fragility fractures in patients 
aged 65 years or under at TSH 3-3.5 mIU/L (hazard 
ratio 0.82 (0.68 to 0.99)).
discussion
In this analysis using repeated measures of TSH 
concentration over time, we investigated whether 
maintaining TSH at different concentrations across 
the “normal” and “abnormal” range in hypothyroid 
patients was associated with long term adverse 
outcomes. We found no difference in mortality rates 
within the recommended normal TSH range of 0.4-4 
mIU/L; however, mortality was higher in the lowest 
TSH category (<0.1 mIU/L) and for concentrations 
above 4 mIU/L. Similarly, we observed no increase in 
risk of ischaemic heart disease, heart failure, stroke/
transient ischaemic attack, atrial fibrillation, and 
fractures in patients with hypothyroidism across TSH 
concentrations within the specified normal range. 
The risk of heart failure was elevated when TSH was 
above 10 mIU/L and lower when TSH was below 
0.4 mIU/L. Interestingly, we found a higher risk of 
fragility fractures for TSH above 10 mIU/L, driven 
predominantly by women and patients aged over 65 
years.
We explored whether the findings were robust in sex 
and age specific analyses. The cardiovascular effects 
of subclinical hyperthyroidism and hypothyroidism 
have been studied in great detail,37 38 and evidence 
suggests that these may be age related,39 40 although 
this has not been universally confirmed.41 Age seems 
to have a rather neutral effect when variation of thyroid 
function within the reference range is studied.42 43 We 
found little evidence to suggest a differential pattern 
of response on the basis of sex or age within the 
recommended normal range. Some evidence existed 
of reduced risk of stroke/transient ischaemic attack 
in women and patients aged over 65 years when TSH 
concentrations were within 3-4 mIU/L, but this was 
offset by a higher risk of atrial fibrillation in those 
aged over 65 years. At TSH 3-3.5 mIU/L, we also found 
some evidence of a decrease in mortality in men and 
a decrease in risk of fracture in patients aged 65 years 
or under. These findings may be the result of multiple 
testing, although each result occurs within the 3-4 
mIU/L concentration range.
In clinical terms, these findings corroborate the 
current recommendations for management of hypothy-
roid patients. However, by showing effects on all 
cause mortality when hypothyroidism is suboptimally 
treated, our findings challenge the notion of a 
“benign” disease and underline the need for diligent 
monitoring, which is sometimes overlooked during the 
long course of the disease in real life scenarios. In the 
study dataset, 11.6% and 32.4% of the annual TSH 
measures were below (<0.4 mIU/L) or above (>4 mIU/L) 
the recommended optimal range, respectively, which is 
largely in line with previous relevant reports.44
strengths and limitations of study
To our knowledge, this is the first study that has taken 
variation of TSH concentrations over time (years) into 
account in the design. An earlier study by Flynn et al 
included multiple TSH measures for each patient but 
table 2 | sex specific incidence rates of cardiovascular diseases, atrial fibrillation, fractures, and mortality
Outcomes
no of patients (person years) no of outcomes incidence rate per 10 000 person years
Men Women Men Women Men Women all
iHD 30 273 (178 000) 114 888 (779 059) 1500 3024 84.27 38.82 47.27
Heart failure 34 861 (209 124) 120 349 (825 738) 1338 2424 63.98 29.36 36.35
Stroke/TiA 34 354 (203 721) 118 270 (804 929) 1395 3827 68.48 47.54 51.77
Atrial fibrillation 33 222 (197 964) 118 429 (808 058) 1674 3836 84.56 47.47 54.77
All fractures 28 862 (169 788) 100 916 (672 025) 1528 8857 89.99 131.79 123.36
Fragility fractures 34 429 (204 920) 112 346 (759 068) 1007 6121 49.14 80.64 73.94
Mortality 37 226 (222 792) 123 213 (846 323) 7555 14 488 339.11 171.19 206.18
iHD=ischaemic heart disease; TiA=transient ischaemic attack.
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used these to create a single weighted mean value that 
was used to assign patients to one of four categories 
(suppressed, low, normal, and high TSH)6; the method 
did not account for changes in TSH concentration or 
category during the follow-up period. The results 
obtained using our methods are reassuring and suggest 
that misclassification bias, resulting from different 
TSH concentrations during the course of life in any 
individual, had a minimal effect on the outcomes 
studied. This, combined with the rigorous selection 
of covariates and a large and well powered study 
population, enabled us to explore a comprehensive 
list of relevant outcomes reflecting the full spectrum of 
cardiovascular disease.
However, the findings should be interpreted in the 
context of the limitations of the study. Firstly, we did 
not differentiate the cause of hypothyroidism (for exam 
ple, autoimmune, post-radioiodine or thyroidectomy, 
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Fig 1 | Hazard ratios with 95% cis for each of seven outcomes for different thyroid stimulating hormone (tsH) categories relative to 2-2.5 miu/l 
reference category. tia=transient ischaemic attack
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and thyroiditis). Furthermore, assay variability, 
potential interference with rheumatoid factors or 
heterophilic antibodies, occasional cases of macro-
TSH, the observed age related shift towards higher 
TSH concentrations in older iodine sufficient patients, 
and obesity may affect this population based sample 
to an extent.45-48 As we could not confirm diagnoses, 
a small proportion of patients with subclinical 
hypothyroidism may have been miscoded as having 
hypothyroidism in general practice. We treated TSH 
as a time varying covariate; for other variables, we 
included baseline values in the model, but these too 
(for example, smoking status, body mass index, and 
drugs) may have varied over time. The median follow-
up period was six years; this may not be sufficient to 
observe all long term outcomes. However, observing 
that the detrimental effects become apparent when 
TSH concentrations dissociate from normal limits, 
we can be relatively confident that the results reflect 
a true effect (type I error is minimal). Cause specific 
mortality is not recorded in THIN, so we could not 
ascertain cause of death. The increase in mortality 
observed at high TSH concentrations could be the 
result of cardiovascular disease resulting in sudden 
death that is not captured in the database (cause 
specific mortality). The possibility of reverse causality 
also exists, whereby the last TSH measurement close to 
death may have been aberrant. In the primary analysis, 
we did not exclude patients with pituitary disease, in 
whom TSH concentrations may not accurately reflect 
circulating thyroid hormone concentrations owing to 
TSH deficiency being caused by inadequate secretion 
of TSH. However, we did a sensitivity analysis for the 
mortality outcome in which we excluded the 1416 
(0.9%) patients with a record of pituitary disease; this 
had no effect on the findings. Osteoporosis is poorly 
recorded in primary care, so we could not include 
osteoporosis as an outcome; we used fragility fracture 
as an alternative.
implications of findings
Our findings may have important implications for 
research and clinical practice. The finding that long 
term outcomes remain similar across a wide range 
of “normal” TSH concentrations supports flexibility 
in the levothyroxine dosing schemes to preserve 
TSH within the normal range. Extrapolating, this is 
also supportive of the not uncommonly overlooked 
importance of an individual’s set point in thyroid 
homoeostasis, as opposed to the laboratory reference.7 
Related to the above, the local, tissue level activation or 
inactivation of thyroid hormones by deiodination (D2 
and D3 deiodinases, which are critical determinants of 
the cytoplasmic triiodothyronine pool49) may provide 
the individual with the necessary buffering capacity to 
control the activation of thyroid receptors at the tissue 
level according to the individual’s needs, provided 
that this buffering capacity is not overwhelmed by 
high or low hormone concentrations. From a clinical 
perspective, this study provides strong support for the 
current recommendations on the clinical management 
of hypothyroid patients and validates with hard 
evidence the latest American Thyroid Association and 
British Thyroid Association guidelines.7 8
conclusions
Using repeated measures of TSH concentration over 
time in a well balanced and highly powered study 
population, we observed no clinically meaningful 
difference in the pattern of long term health outcomes, 
including all cause mortality, heart failure, ischaemic 
heart disease, stroke/transient ischaemic attack, 
atrial fibrillation, all fractures, and fragility fractures, 
in patients with a diagnosis of hypothyroidism when 
TSH concentrations lie within normal limits. However, 
targets for individual patients should be considered in 
line with their clinical needs.
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